BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37847858)

  • 1. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M; Mundo L; Messina E; Campolo F; Lazzi S; Angeloni A; Marchese C; Leoncini L; Giordano C; Slack F; Trivedi P; Anastasiadou E
    Blood; 2024 Feb; 143(5):429-443. PubMed ID: 37847858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk.
    Kim JH; Kim WS; Hong JY; Ryu KJ; Kim SJ; Park C
    Oncotarget; 2017 Jan; 8(3):5361-5370. PubMed ID: 28036258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2.
    Rosato P; Anastasiadou E; Garg N; Lenze D; Boccellato F; Vincenti S; Severa M; Coccia EM; Bigi R; Cirone M; Ferretti E; Campese AF; Hummel M; Frati L; Presutti C; Faggioni A; Trivedi P
    Leukemia; 2012 Nov; 26(11):2343-52. PubMed ID: 22614176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.
    Boccellato F; Anastasiadou E; Rosato P; Kempkes B; Frati L; Faggioni A; Trivedi P
    J Virol; 2007 Mar; 81(5):2274-82. PubMed ID: 17151114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
    Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
    J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly.
    Stuhlmann-Laeisz C; Borchert A; Quintanilla-Martinez L; Hoeller S; Tzankov A; Oschlies I; Kreuz M; Trappe R; Klapper W
    Leuk Lymphoma; 2016; 57(1):39-44. PubMed ID: 25899404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
    Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
    J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
    Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
    Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
    Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.
    Ma J; Nie K; Redmond D; Liu Y; Elemento O; Knowles DM; Tam W
    Leukemia; 2016 Mar; 30(3):594-604. PubMed ID: 26530011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.
    Kohlhof H; Hampel F; Hoffmann R; Burtscher H; Weidle UH; Hölzel M; Eick D; Zimber-Strobl U; Strobl LJ
    Blood; 2009 May; 113(22):5506-15. PubMed ID: 19339697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.